Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Anticancer Drugs / Niamh M. O'Boyle, Mary J. Meegan
| Anticancer Drugs / Niamh M. O'Boyle, Mary J. Meegan |
| Autore | O'Boyle Niamh M |
| Pubbl/distr/stampa | MDPI - Multidisciplinary Digital Publishing Institute, 2019 |
| Descrizione fisica | 1 electronic resource (214 p.) |
| Soggetto topico | Chemistry |
| Soggetto non controllato |
graphene oxide
indole androgens cyclooxygenase-2 cyclooxygenase-1 heteropolysaccharide drug conjugation drug delivery ellipticine chemical linker oesophageal cancer antiproliferative activity topoisomerase II ?-lactam DSD antibody topoisomerase inhibitors magnetic targeting cisplatin resistance steroidogenesis [18F]FDG PET/CT heterocyclic chemistry dehydroepiandrosterone antimitotic 3-vinylazetidin-2-ones glioblastoma and cancer therapy intestinal mucositis Combretastatin A-4 metabolism anti-cancer drugs maghemite COX-1 inhibitor anticancer CYP17A1 conjugate and hybrid drugs inflammation snticancer drugs P450c17 tumorigenesis cisplatin biomarker profiling cancer drug design tubulin cytochrome P450 5-fluorouracil prostate cancer abiraterone NCI screen radiation cancer immunotherapy microtubule targeted drugs cancer treatment resistance |
| ISBN |
9783039215874
3039215876 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910367753903321 |
O'Boyle Niamh M
|
||
| MDPI - Multidisciplinary Digital Publishing Institute, 2019 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Targeting STAT3 and STAT5 in Cancer
| Targeting STAT3 and STAT5 in Cancer |
| Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 |
| Descrizione fisica | 1 online resource (578 p.) |
| Soggetto topico |
Biology, life sciences
Research & information: general |
| Soggetto non controllato |
ADAM17
adoptive T cell therapy AKT androgens apoptosis autoimmune disease autosomal-dominant hyper IgE syndrome Bone Marrow Failure Syndromes breast cancer cancer cancer models cancer progression cancer-stem cell CD38 CD4+ T cells CD8+ T cells cell cycle cell hierarchy chaperones chemotherapy resistance cirrhosis colon cancer companion animals comparative oncology cytokine cytokine receptor signaling dynamic programming endoplasmic reticulum (ER) stress epidermal growth factor receptor (EGF-R) ERK1/2 escape mechanisms gain-of-function mutation glioblastoma glioma growth hormone insensitivity syndrome heat shock proteins hedging hematopoietic cancers hepatitis C virus (HCV) hepatocellular carcinoma (HCC) hepatocyte nuclear factor 4 alpha (HNF4A) immune check point immune suppression immunosuppression immunotherapy inflammation inflammation associated cancer inflammatory hepatocellular adenomas interleukin-6 JAK JAK family of protein tyrosine kinases JAK2 V617F knockout lipopolyplex lung cancer lymphocytes lymphoma M2 macrophages melanoma meta-analysis metalloprotease metastasis microRNA-122 (miR-122) mitochondria MPN mTOR multiple myeloma mutations myeloid cells myeloid leukemia n/a nanoparticle neoplastic stem cells NGS NK cells nuclear factor erythroid 2-related factor 2 (NRF2) nuclear pore complex nuclear transport receptors nucleocytoplasmic shuttling ovarian cancer oxidative stress (OS) PD-L1 PEI pharmacological inhibitor pharmacological inhibitors polyethylenimine post-decision state variable prolactin proliferation prostate cancer RHOA risk management S3I-1757 SH2 domain shedding signal transducer and activator of transcription signal transducer and activator of transcription 3 (STAT3) siRNA delivery siRNA/RNAi small-molecule inhibitors solid cancers stabilization STAT STAT transcription factors STAT3 STAT3 inhibitor XIII STAT5 STAT5 signaling STAT5B signaling stem/progenitor cells stemness T-cell large granular lymphocytic leukemia T-cell leukemia T-cell prolymphocytic leukemia T-cells T-PLL targeted therapy targeting therapeutic targeting therapy resistance trans-signaling transaction costs tumor microenvironment tumor necrosis factor alpha (TNFα) tumor suppression tumor-associated macrophages tumor-immune cell interactions tumorigenesis tyrosine kinase 2 unfolded protein response (UPR) |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910557623503321 |
| Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||